AtriCure initiated with an Outperform at JMP Securities

JMP Securities analyst Daniel Stauder initiated coverage of AtriCure with an Outperform rating and $60 price target. As the number one player in treating complex forms of atrial fibrillation, AtriCure has carved out a dominant position in two major legacy cardiac arenas that are still growing at a “very healthy clip, and where it is primarily the only game in town,” the analyst tells investors in a research note. The firm says the company also has two emerging opportunities that represent even larger total addressable markets than its historical arenas.